Login to Your Account



Viamet, Novartis Fund Targeting Metalloenzymes in $200M Deal

By Catherine Hollingsworth


Tuesday, February 23, 2010
Viamet Pharmaceuticals Inc. signed a deal worth more than $200 million with the Novartis Option Fund to discover and develop metalloenzyme inhibitors of interest to the Swiss drugmaker. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription